# Ascendum Capital

> Ascendum Capital is a VC fund in Hong Kong backing Health Care and Medical Device. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Hong Kong, Hong Kong
- Total investments: 3
- Last investment: Jan 2023
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/ascendum-capital/

Ascendum Capital is a healthcare-focused investment firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 100% |
| Medical Device | 2 | 67% |
| Medical | 1 | 33% |
| Hospital | 1 | 33% |
| Health Diagnostics | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 67% |
| Series C | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 2 | 67% |
| United States | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Tingsheng Technology | TINGSN develops Intracardiac echocardiography (ICE) catheter imaging technology designed to treat cardiac arrhythmia. In addition to ICE products, the company has developed its own heart internal catheter positioning and software algorithms and is developing China first computer surgical simulator for cardiac electrophysiology based on digitalheart model. | $14.7M | Series B | Jan 29, 2023 |  |
| Valgen Medtech | Valgen focus on treatment technologies and systemic solutions for heart disease, especially for mitral and tricuspid valve lesions. | $188M | Series B | May 06, 2021 |  |
| Broncus Technologies | Broncus Technologies is a medical technology company focused on developing minimally-invasive medical devices for emphysema and other lung diseases. Broncus is investigating the Exhale emphysema product line to perform our patented treatment method called Airway Bypass. Airway Bypass could be the first minimally-invasive procedure for the treatmentof homogeneous, or diffuse, emphysema, which constitutes the majority of the emphysema patient population.Broncus is currently enrolling patients worldwide in our pivotal EASE Trial investigating a treatment of severe homogeneous emphysema.Broncus is located in Mountain View, CA (San Francisco Bay area).Broncus International is located in Nyon, Switzerland. |  | Series C | Oct 14, 2020 |  |

3 of 3 investments shown.

## Co-investors
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 3 deals together
- [DCP Capital](https://shizune.co/investors/profile/dcp-capital) — VC Fund, 2 deals together
- [Lake Bleu Capital](https://shizune.co/investors/profile/lake-bleu-capital) — VC Fund, 2 deals together
- [Baidu Capital](https://shizune.co/investors/profile/baidu-capital) — VC Fund, 1 deal together
- [China Life Insurance](https://shizune.co/investors/profile/china-life) — VC Fund, 1 deal together
- China Life Healthcare Fund — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Ascendum Capital invest in?

Ascendum Capital invests primarily in Health Care, Medical Device and Medical startups, most often at Series B and Series C stage. Most of the 3 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ascendum Capital last invest?

The most recent investment recorded for Ascendum Capital closed in Jan 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co